Literature DB >> 33471974

A Population-Based Study of Genes Previously Implicated in Breast Cancer.

Chunling Hu1, Steven N Hart1, Rohan Gnanaolivu1, Hongyan Huang1, Kun Y Lee1, Jie Na1, Chi Gao1, Jenna Lilyquist1, Siddhartha Yadav1, Nicholas J Boddicker1, Raed Samara1, Josh Klebba1, Christine B Ambrosone1, Hoda Anton-Culver1, Paul Auer1, Elisa V Bandera1, Leslie Bernstein1, Kimberly A Bertrand1, Elizabeth S Burnside1, Brian D Carter1, Heather Eliassen1, Susan M Gapstur1, Mia Gaudet1, Christopher Haiman1, James M Hodge1, David J Hunter1, Eric J Jacobs1, Esther M John1, Charles Kooperberg1, Allison W Kurian1, Loic Le Marchand1, Sara Lindstroem1, Tricia Lindstrom1, Huiyan Ma1, Susan Neuhausen1, Polly A Newcomb1, Katie M O'Brien1, Janet E Olson1, Irene M Ong1, Tuya Pal1, Julie R Palmer1, Alpa V Patel1, Sonya Reid1, Lynn Rosenberg1, Dale P Sandler1, Christopher Scott1, Rulla Tamimi1, Jack A Taylor1, Amy Trentham-Dietz1, Celine M Vachon1, Clarice Weinberg1, Song Yao1, Argyrios Ziogas1, Jeffrey N Weitzel1, David E Goldgar1, Susan M Domchek1, Katherine L Nathanson1, Peter Kraft1, Eric C Polley1, Fergus J Couch1.   

Abstract

BACKGROUND: Population-based estimates of the risk of breast cancer associated with germline pathogenic variants in cancer-predisposition genes are critically needed for risk assessment and management in women with inherited pathogenic variants.
METHODS: In a population-based case-control study, we performed sequencing using a custom multigene amplicon-based panel to identify germline pathogenic variants in 28 cancer-predisposition genes among 32,247 women with breast cancer (case patients) and 32,544 unaffected women (controls) from population-based studies in the Cancer Risk Estimates Related to Susceptibility (CARRIERS) consortium. Associations between pathogenic variants in each gene and the risk of breast cancer were assessed.
RESULTS: Pathogenic variants in 12 established breast cancer-predisposition genes were detected in 5.03% of case patients and in 1.63% of controls. Pathogenic variants in BRCA1 and BRCA2 were associated with a high risk of breast cancer, with odds ratios of 7.62 (95% confidence interval [CI], 5.33 to 11.27) and 5.23 (95% CI, 4.09 to 6.77), respectively. Pathogenic variants in PALB2 were associated with a moderate risk (odds ratio, 3.83; 95% CI, 2.68 to 5.63). Pathogenic variants in BARD1, RAD51C, and RAD51D were associated with increased risks of estrogen receptor-negative breast cancer and triple-negative breast cancer, whereas pathogenic variants in ATM, CDH1, and CHEK2 were associated with an increased risk of estrogen receptor-positive breast cancer. Pathogenic variants in 16 candidate breast cancer-predisposition genes, including the c.657_661del5 founder pathogenic variant in NBN, were not associated with an increased risk of breast cancer.
CONCLUSIONS: This study provides estimates of the prevalence and risk of breast cancer associated with pathogenic variants in known breast cancer-predisposition genes in the U.S. population. These estimates can inform cancer testing and screening and improve clinical management strategies for women in the general population with inherited pathogenic variants in these genes. (Funded by the National Institutes of Health and the Breast Cancer Research Foundation.).
Copyright © 2021 Massachusetts Medical Society.

Entities:  

Mesh:

Year:  2021        PMID: 33471974      PMCID: PMC8127622          DOI: 10.1056/NEJMoa2005936

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  40 in total

1.  Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.

Authors:  Susan M Domchek; Tara M Friebel; Christian F Singer; D Gareth Evans; Henry T Lynch; Claudine Isaacs; Judy E Garber; Susan L Neuhausen; Ellen Matloff; Rosalind Eeles; Gabriella Pichert; Laura Van t'veer; Nadine Tung; Jeffrey N Weitzel; Fergus J Couch; Wendy S Rubinstein; Patricia A Ganz; Mary B Daly; Olufunmilayo I Olopade; Gail Tomlinson; Joellen Schildkraut; Joanne L Blum; Timothy R Rebbeck
Journal:  JAMA       Date:  2010-09-01       Impact factor: 56.272

2.  Lynch syndrome caused by MLH1 mutations is associated with an increased risk of breast cancer: a cohort study.

Authors:  Elaine F Harkness; Emma Barrow; Katy Newton; Kate Green; Tara Clancy; Fiona Lalloo; James Hill; D Gareth Evans
Journal:  J Med Genet       Date:  2015-06-22       Impact factor: 6.318

3.  Rare mutations in XRCC2 increase the risk of breast cancer.

Authors:  D J Park; F Lesueur; T Nguyen-Dumont; M Pertesi; F Odefrey; F Hammet; S L Neuhausen; E M John; I L Andrulis; M B Terry; M Daly; S Buys; F Le Calvez-Kelm; A Lonie; B J Pope; H Tsimiklis; C Voegele; F M Hilbers; N Hoogerbrugge; A Barroso; A Osorio; G G Giles; P Devilee; J Benitez; J L Hopper; S V Tavtigian; D E Goldgar; M C Southey
Journal:  Am J Hum Genet       Date:  2012-03-29       Impact factor: 11.025

4.  A Recurrent ERCC3 Truncating Mutation Confers Moderate Risk for Breast Cancer.

Authors:  Joseph Vijai; Sabine Topka; Danylo Villano; Vignesh Ravichandran; Kara N Maxwell; Ann Maria; Tinu Thomas; Pragna Gaddam; Anne Lincoln; Sarah Kazzaz; Brandon Wenz; Shai Carmi; Kasmintan A Schrader; Steven N Hart; Steve M Lipkin; Susan L Neuhausen; Michael F Walsh; Liying Zhang; Flavio Lejbkowicz; Hedy Rennert; Zsofia K Stadler; Mark Robson; Jeffrey N Weitzel; Susan Domchek; Mark J Daly; Fergus J Couch; Katherine L Nathanson; Larry Norton; Gad Rennert; Kenneth Offit
Journal:  Cancer Discov       Date:  2016-09-21       Impact factor: 39.397

5.  Rare mutations in RINT1 predispose carriers to breast and Lynch syndrome-spectrum cancers.

Authors:  Daniel J Park; Kayoko Tao; Florence Le Calvez-Kelm; Tu Nguyen-Dumont; Nivonirina Robinot; Fleur Hammet; Fabrice Odefrey; Helen Tsimiklis; Zhi L Teo; Louise B Thingholm; Erin L Young; Catherine Voegele; Andrew Lonie; Bernard J Pope; Terrell C Roane; Russell Bell; Hao Hu; Chad D Huff; Jonathan Ellis; Jun Li; Igor V Makunin; Esther M John; Irene L Andrulis; Mary B Terry; Mary Daly; Saundra S Buys; Carrie Snyder; Henry T Lynch; Peter Devilee; Graham G Giles; John L Hopper; Bing-Jian Feng; Fabienne Lesueur; Sean V Tavtigian; Melissa C Southey; David E Goldgar
Journal:  Cancer Discov       Date:  2014-05-02       Impact factor: 39.397

6.  Exome sequencing identifies FANCM as a susceptibility gene for triple-negative breast cancer.

Authors:  Johanna I Kiiski; Liisa M Pelttari; Sofia Khan; Edda S Freysteinsdottir; Inga Reynisdottir; Steven N Hart; Hermela Shimelis; Sara Vilske; Anne Kallioniemi; Johanna Schleutker; Arto Leminen; Ralf Bützow; Carl Blomqvist; Rosa B Barkardottir; Fergus J Couch; Kristiina Aittomäki; Heli Nevanlinna
Journal:  Proc Natl Acad Sci U S A       Date:  2014-10-06       Impact factor: 11.205

7.  Cost-effectiveness of Population-Based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 Mutation Testing in Unselected General Population Women.

Authors:  Ranjit Manchanda; Shreeya Patel; Vladimir S Gordeev; Antonis C Antoniou; Shantel Smith; Andrew Lee; John L Hopper; Robert J MacInnis; Clare Turnbull; Susan J Ramus; Simon A Gayther; Paul D P Pharoah; Usha Menon; Ian Jacobs; Rosa Legood
Journal:  J Natl Cancer Inst       Date:  2018-07-01       Impact factor: 13.506

8.  Gene-panel sequencing and the prediction of breast-cancer risk.

Authors:  Douglas F Easton; Paul D P Pharoah; Antonis C Antoniou; Marc Tischkowitz; Sean V Tavtigian; Katherine L Nathanson; Peter Devilee; Alfons Meindl; Fergus J Couch; Melissa Southey; David E Goldgar; D Gareth R Evans; Georgia Chenevix-Trench; Nazneen Rahman; Mark Robson; Susan M Domchek; William D Foulkes
Journal:  N Engl J Med       Date:  2015-05-27       Impact factor: 91.245

9.  A clinical guide to hereditary cancer panel testing: evaluation of gene-specific cancer associations and sensitivity of genetic testing criteria in a cohort of 165,000 high-risk patients.

Authors:  Holly LaDuca; Eric C Polley; Amal Yussuf; Lily Hoang; Stephanie Gutierrez; Steven N Hart; Siddhartha Yadav; Chunling Hu; Jie Na; David E Goldgar; Kelly Fulk; Laura Panos Smith; Carolyn Horton; Jessica Profato; Tina Pesaran; Chia-Ling Gau; Melissa Pronold; Brigette Tippin Davis; Elizabeth C Chao; Fergus J Couch; Jill S Dolinsky
Journal:  Genet Med       Date:  2019-08-13       Impact factor: 8.822

10.  MSH6 and PMS2 germ-line pathogenic variants implicated in Lynch syndrome are associated with breast cancer.

Authors:  Maegan E Roberts; Sarah A Jackson; Lisa R Susswein; Nur Zeinomar; Xinran Ma; Megan L Marshall; Amy R Stettner; Becky Milewski; Zhixiong Xu; Benjamin D Solomon; Mary Beth Terry; Kathleen S Hruska; Rachel T Klein; Wendy K Chung
Journal:  Genet Med       Date:  2018-01-18       Impact factor: 8.822

View more
  94 in total

1.  PALB2 germline mutations in a multi-gene panel testing cohort of 1905 breast-ovarian cancer patients in Argentina.

Authors:  Ariana Gonzalez; Franco Del Greco; Laura Vargas-Roig; Bianca Brun; Gonzalo Tabares; Alejandra Mampel; Cecilia Montes; Claudia Martin; Marcela Lopez; Norma Rossi; Luisina Bruno; Carolina Ponce; Patricia Quaglio; Alvaro Yanzi; Santiago Acevedo; Lilia Lugo; Paula Lopez Breccia; Silvia Avila; Silvina Sisterna; María Soledad Del Castillo; Martín Vazquez; Lina M Nuñez
Journal:  Breast Cancer Res Treat       Date:  2022-05-24       Impact factor: 4.872

2.  Association of Family Cancer History With Pathogenic Variants in Specific Breast Cancer Susceptibility Genes.

Authors:  Allison W Kurian; Paul Abrahamse; Kevin C Ward; Ann S Hamilton; Dennis Deapen; Jonathan S Berek; Lily Hoang; Amal Yussuf; Jill Dolinsky; Krystal Brown; Thomas Slavin; Timothy P Hofer; Steven J Katz
Journal:  JCO Precis Oncol       Date:  2021-12-22

Review 3.  Current status of AYA-generation breast cancer: trends worldwide and in Japan.

Authors:  Manabu Futamura; Kazuhiro Yoshida
Journal:  Int J Clin Oncol       Date:  2021-12-18       Impact factor: 3.402

4.  Investigation of Interferon Gamma Activity Using Bioinformatics Methods.

Authors:  N E Hassan; A A Al-Janabi
Journal:  Arch Razi Inst       Date:  2021-11-30

5.  Germline Pathogenic Variants in Cancer Predisposition Genes Among Women With Invasive Lobular Carcinoma of the Breast.

Authors:  Siddhartha Yadav; Chunling Hu; Katherine L Nathanson; Jeffrey N Weitzel; David E Goldgar; Peter Kraft; Rohan D Gnanaolivu; Jie Na; Hongyan Huang; Nicholas J Boddicker; Nicole Larson; Chi Gao; Song Yao; Clarice Weinberg; Celine M Vachon; Amy Trentham-Dietz; Jack A Taylor; Dale R Sandler; Alpa Patel; Julie R Palmer; Janet E Olson; Susan Neuhausen; Elena Martinez; Sara Lindstrom; James V Lacey; Allison W Kurian; Esther M John; Christopher Haiman; Leslie Bernstein; Paul W Auer; Hoda Anton-Culver; Christine B Ambrosone; Rachid Karam; Elizabeth Chao; Amal Yussuf; Tina Pesaran; Jill S Dolinsky; Steven N Hart; Holly LaDuca; Eric C Polley; Susan M Domchek; Fergus J Couch
Journal:  J Clin Oncol       Date:  2021-10-21       Impact factor: 44.544

6.  Cancer in Children With Fanconi Anemia and Ataxia-Telangiectasia-A Nationwide Register-Based Cohort Study in Germany.

Authors:  Christina M Dutzmann; Claudia Spix; Isabell Popp; Melanie Kaiser; Friederike Erdmann; Miriam Erlacher; Thilo Dörk; Detlev Schindler; Reinhard Kalb; Christian P Kratz
Journal:  J Clin Oncol       Date:  2021-10-01       Impact factor: 44.544

Review 7.  Towards population-based genetic screenings for breast and ovarian cancer: A comprehensive review from economic evaluations to patient perspectives.

Authors:  Filomena Ficarazzi; Manuela Vecchi; Maurizio Ferrari; Marco A Pierotti
Journal:  Breast       Date:  2021-05-12       Impact factor: 4.380

8.  Revisiting the Implications of Positive Germline Testing Results Using Multi-gene Panels in Breast Cancer Patients.

Authors:  Georgios N Tsaousis; Eirini Papadopoulou; Konstantinos Agiannitopoulos; Georgia Pepe; Nikolaos Tsoulos; Ioannis Boukovinas; Theofanis Floros; Rodoniki Iosifidou; Ourania Katopodi; Anna Koumarianou; Christos Markopoulos; Konstantinos Papazisis; Vasileios Venizelos; Achilleas Kapsimalis; Grigorios Xepapadakis; Amanda Psyrri; Eugeniu Banu; Dan Tudor Eniu; Alexandru Blidaru; Dana Lucia Stanculeanu; Andrei Ungureanu; Vahit Ozmen; Sualp Tansan; Mehmet Tekinel; Suayib Yalcin; George Nasioulas
Journal:  Cancer Genomics Proteomics       Date:  2022 Jan-Feb       Impact factor: 4.069

Review 9.  Understanding the Clinical Implications of Low Penetrant Genes and Breast Cancer Risk.

Authors:  Anusha Vaidyanathan; Virginia Kaklamani
Journal:  Curr Treat Options Oncol       Date:  2021-08-23

Review 10.  Differences in Ovarian and Other Cancers Risks by Population and BRCA Mutation Location.

Authors:  Masayuki Sekine; Koji Nishino; Takayuki Enomoto
Journal:  Genes (Basel)       Date:  2021-07-08       Impact factor: 4.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.